Reagents
Reagents are the major cost contributor in mRNA-based therapy manufacture. Access is limited by intellectual property rights that protect specific chemistries and compositions. Quantoom’s objective is to drastically reduce the raw material-related costs to ensure affordable access to RNA technology by:
securing long-term supply agreements at low prices for non-proprietary reagents
investigating alternative solutions for proprietary reagents (e.g. auxiliary technologies, development and improvement of new proprietary reagents, etc.)
We are fully committed to provide reagents with the highest levels of quality and performance. Not only is the secure supply of critical reagents our priority, but we are also developing our own alternatives to meet these ambitious goals.
An example
The DNA polymerase enzyme is essential for the production of DNA, which is in turn a critical raw material for RNA synthesis. High-fidelity DNA polymerases are therefore key for the manufacturing of mRNA vaccines. Our development plan pipeline includes the improvement of a free-to-operate DNA polymerase to provide an ultra-high-fidelity enzyme that bypasses the complex E. coli-based large-scale manufacture of plasmid DNA.
In addition, Quantoom Biosciences will offer ready-to-use reagent mixes for each of our systems in both research and GMP-grades.
An example
The DNA polymerase enzyme is essential for the production of DNA, which is in turn a critical raw material for RNA synthesis. High-fidelity DNA polymerases are therefore key for the manufacturing of mRNA vaccines. Our development plan pipeline includes the improvement of a free-to-operate DNA polymerase to provide an ultra-high-fidelity enzyme that bypasses the complex E. coli-based large-scale manufacture of plasmid DNA.
In addition, Quantoom Biosciences will offer ready-to-use reagent mixes for each of our systems in both research and GMP-grades.
